Skip to main content
Top
Published in: BMC Palliative Care 1/2016

Open Access 01-12-2016 | Research article

Management of non-ovarian cancer malignant ascites through indwelling catheter drainage

Authors: Xiaoli Gu, Yuanyuan Zhang, Menglei Cheng, Minghui Liu, Zhe Zhang, Wenwu Cheng

Published in: BMC Palliative Care | Issue 1/2016

Login to get access

Abstract

Backgrounds

Intra-abdominal placement of the Central Venous Catheter (CVC) was conducted to manage the ascites-related symptoms of non-ovarian cancer patients. The aim of this study is to document the efficacy of symptom relief and conduct survival analysis of non-ovarian cancer patients with malignant ascites who received paracentesis and indwelling catheter drainage.

Methods

Seventy eight patients received paracentesis and drainage. All patients who met the inclusion criteria were included in this study. The overall survival (OS) was defined as the interval between initial diagnosis and death. Since-paracentesis survival (SP-Survival) was defined as the interval between initial paracentesis and death.

Results

Hepatic cancer was the most frequent original cancer in this study. Peritoneal catheters remained in situ for a median of 13 days. No immediate complications, such as perforation of a viscus or excessive bleeding, were encountered during placement. All ascites-related symptoms improved after drainage compared with the baseline. There was a statistically significant improvement in the mean score for abdominal swelling (p < 0.001), anorexia (p = 0.023) and constipation (p = 0.045). Cancer type was shown to be an independent prognostic factor for overall survival length (p = 0.001). Serum albumin was an independent prognostic factor for SP-survival (p = 0.02).

Conclusions

Paracentesis and indwelling catheter drainage through CVC set is a useful method for improving painful symptom. Further research is needed to validate the findings.
Literature
1.
go back to reference Adam RA, Adam YG. Malignant ascites: Past, present, and future. J Am Coll Surg. 2004;198:999–1011.CrossRefPubMed Adam RA, Adam YG. Malignant ascites: Past, present, and future. J Am Coll Surg. 2004;198:999–1011.CrossRefPubMed
3.
go back to reference Cella D, Neubauer N, Thomas J, Kutner J, Seiden MV. The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecol Oncol. 2013;128:187–90.CrossRefPubMed Cella D, Neubauer N, Thomas J, Kutner J, Seiden MV. The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecol Oncol. 2013;128:187–90.CrossRefPubMed
4.
go back to reference Day R, Mitchell T, Keen A, Perkins P. The experiences of patients with ascites secondary to cancer: a qualitative study. Palliat Med. 2013;27:739–46.CrossRefPubMed Day R, Mitchell T, Keen A, Perkins P. The experiences of patients with ascites secondary to cancer: a qualitative study. Palliat Med. 2013;27:739–46.CrossRefPubMed
5.
go back to reference Brescia RJ, Barakat RA, Beller U, Frederickson G, Suhrland MJ, Dubin N, et al. The prognostic significant of nuclear-DNA content in malignant epithelial tumors of the ovary. Cancer. 1990;65:141–7.CrossRefPubMed Brescia RJ, Barakat RA, Beller U, Frederickson G, Suhrland MJ, Dubin N, et al. The prognostic significant of nuclear-DNA content in malignant epithelial tumors of the ovary. Cancer. 1990;65:141–7.CrossRefPubMed
6.
go back to reference Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87–95.CrossRefPubMedPubMedCentral Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87–95.CrossRefPubMedPubMedCentral
7.
go back to reference Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82:532–7.CrossRefPubMed Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82:532–7.CrossRefPubMed
8.
go back to reference Schmalfeldt B, Seck K, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Geburtshilfe Frauenheilkd. 2012;72. Schmalfeldt B, Seck K, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Geburtshilfe Frauenheilkd. 2012;72.
9.
go back to reference Ehlken B, Berger K, Shlaen R, Gonschior AK, Lordick F. Management of malignant ascites in Germany-Treatment patterns, resource consumption, and costs. Value Health. 2010;13:A263–A263.CrossRef Ehlken B, Berger K, Shlaen R, Gonschior AK, Lordick F. Management of malignant ascites in Germany-Treatment patterns, resource consumption, and costs. Value Health. 2010;13:A263–A263.CrossRef
10.
go back to reference Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23:1979–85.CrossRefPubMedPubMedCentral Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23:1979–85.CrossRefPubMedPubMedCentral
11.
go back to reference Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79:144–53.CrossRefPubMed Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79:144–53.CrossRefPubMed
12.
go back to reference Saada E, Follana P, Peyrade F, Mari V, François E. Pathogenesis and management of refractory malignant ascites. Bull Cancer. 2011;98:679–87.PubMed Saada E, Follana P, Peyrade F, Mari V, François E. Pathogenesis and management of refractory malignant ascites. Bull Cancer. 2011;98:679–87.PubMed
13.
go back to reference Macdonald R, Kirwan J, Roberts S, Gray D, Allsopp L, Green J. Ovarian cancer and ascites: A questionnaire on current management in the United Kingdom. J Palliat Med. 2006;9:1264–70.CrossRefPubMed Macdonald R, Kirwan J, Roberts S, Gray D, Allsopp L, Green J. Ovarian cancer and ascites: A questionnaire on current management in the United Kingdom. J Palliat Med. 2006;9:1264–70.CrossRefPubMed
14.
go back to reference Lungren MP, Kim CY, Stewart JK, Smith TP, Miller MJ. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. J Vasc Interv Radiol. 2013;24:1303–8.CrossRefPubMed Lungren MP, Kim CY, Stewart JK, Smith TP, Miller MJ. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. J Vasc Interv Radiol. 2013;24:1303–8.CrossRefPubMed
15.
go back to reference Coupe NA, Cox K, Clark K, Boyer M, Stockler M. Outcomes of permanent peritoneal ports for the management of recurrent malignant ascites. J Palliat Med. 2013;16:938–40.CrossRefPubMed Coupe NA, Cox K, Clark K, Boyer M, Stockler M. Outcomes of permanent peritoneal ports for the management of recurrent malignant ascites. J Palliat Med. 2013;16:938–40.CrossRefPubMed
16.
go back to reference Mercadante S, Intravaia G, Ferrera P, Villari P, David F. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Supportive Care Cancer. 2008;16:975–8.CrossRef Mercadante S, Intravaia G, Ferrera P, Villari P, David F. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Supportive Care Cancer. 2008;16:975–8.CrossRef
17.
go back to reference Van Thiel DH, Moore CM, Garcia M, George M, Nadir A. Continuous peritoneal drainage of large-volume ascites. Dig Dis Sci. 2011;56:2723–7.CrossRefPubMed Van Thiel DH, Moore CM, Garcia M, George M, Nadir A. Continuous peritoneal drainage of large-volume ascites. Dig Dis Sci. 2011;56:2723–7.CrossRefPubMed
18.
go back to reference Den Hollander BS, Connolly BL, Sung L, Rapoport A, Zwaan CM, Grant RM, et al. Successful use of indwelling tunneled catheters for the management of effusions in children with advanced cancer. Pediatr Blood Cancer. 2014;61:1007–12.CrossRef Den Hollander BS, Connolly BL, Sung L, Rapoport A, Zwaan CM, Grant RM, et al. Successful use of indwelling tunneled catheters for the management of effusions in children with advanced cancer. Pediatr Blood Cancer. 2014;61:1007–12.CrossRef
19.
go back to reference Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manag. 2009;38:341–9.CrossRef Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manag. 2009;38:341–9.CrossRef
20.
go back to reference Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer. 2006;42:589–97.CrossRefPubMed Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer. 2006;42:589–97.CrossRefPubMed
21.
go back to reference Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Med. 2012;29:515–21.CrossRef Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Med. 2012;29:515–21.CrossRef
22.
go back to reference Jia W, Zhu Z, Zhang T, Fan G, Fan P, Liu Y, et al. Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. Cancer Chemother Pharmacol. 2013;71:1585–90.CrossRefPubMed Jia W, Zhu Z, Zhang T, Fan G, Fan P, Liu Y, et al. Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. Cancer Chemother Pharmacol. 2013;71:1585–90.CrossRefPubMed
23.
go back to reference Decruze SB, Macdonald R, Smith G, Herod JJ. Paracentesis in ovarian cancer: a study of the physiology during free drainage of ascites. J Palliat Med. 2010;13:251–4.CrossRefPubMed Decruze SB, Macdonald R, Smith G, Herod JJ. Paracentesis in ovarian cancer: a study of the physiology during free drainage of ascites. J Palliat Med. 2010;13:251–4.CrossRefPubMed
24.
go back to reference Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med. 2002;16:213–8.CrossRefPubMed Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med. 2002;16:213–8.CrossRefPubMed
25.
go back to reference Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18:1–9.CrossRefPubMed Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18:1–9.CrossRefPubMed
26.
go back to reference Bui CD, Martin CJ, Currow DC. Case report; effective community palliation of intractable malignant ascites with a permanently implanted abdominal drain. J Palliate Med. 1999;2:319–21.CrossRef Bui CD, Martin CJ, Currow DC. Case report; effective community palliation of intractable malignant ascites with a permanently implanted abdominal drain. J Palliate Med. 1999;2:319–21.CrossRef
27.
go back to reference Mullard AP, Bishop JM, Jibani M. Intractable malignant ascites: An alternative management option. J Palliat Med. 2011;14:251–3.CrossRefPubMed Mullard AP, Bishop JM, Jibani M. Intractable malignant ascites: An alternative management option. J Palliat Med. 2011;14:251–3.CrossRefPubMed
28.
go back to reference Agah S, Tavakoli S, Nikbakht H, Najafi M, Al-Agha A. Central venous pressure catheter for large-volume paracentesis in refractory ascites. Indian J Gastroenterol. 2014;33:310–5.CrossRefPubMed Agah S, Tavakoli S, Nikbakht H, Najafi M, Al-Agha A. Central venous pressure catheter for large-volume paracentesis in refractory ascites. Indian J Gastroenterol. 2014;33:310–5.CrossRefPubMed
29.
go back to reference White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance. Appl Health Econ Health Policy. 2012;10:299–308.CrossRefPubMed White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance. Appl Health Econ Health Policy. 2012;10:299–308.CrossRefPubMed
30.
go back to reference Ye M, Pan HM, Wang HY, Lou F, Jin W, Zheng Y, et al. Catheterization-associated complications of intraperitoneal chemotherapy in advanced gastric cancer. World J Gastroenterol. 2004;10:1372–4.PubMedPubMedCentral Ye M, Pan HM, Wang HY, Lou F, Jin W, Zheng Y, et al. Catheterization-associated complications of intraperitoneal chemotherapy in advanced gastric cancer. World J Gastroenterol. 2004;10:1372–4.PubMedPubMedCentral
31.
go back to reference Rozenblit GN, Del Guercio LRM, Rundback JH, Poplausky MR, Lebovics E. Peritoneal-urinary drainage for treatment of refractory ascites: A pilot study. J Vasc Interv Radiol. 1998;9:998–1005.CrossRefPubMed Rozenblit GN, Del Guercio LRM, Rundback JH, Poplausky MR, Lebovics E. Peritoneal-urinary drainage for treatment of refractory ascites: A pilot study. J Vasc Interv Radiol. 1998;9:998–1005.CrossRefPubMed
32.
go back to reference O'Neill MJ, Weissleder R, Gervais DA, Hahn PF, Mueller PR, Lebovics E. Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites. AJR Am J Roentgenol. 2001;177:615–8.CrossRefPubMed O'Neill MJ, Weissleder R, Gervais DA, Hahn PF, Mueller PR, Lebovics E. Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites. AJR Am J Roentgenol. 2001;177:615–8.CrossRefPubMed
33.
go back to reference Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. Supportive Care Cancer. 2000;8:493–9. Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. Supportive Care Cancer. 2000;8:493–9.
34.
go back to reference Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Solà R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol. 2004;16:347–53.CrossRefPubMed Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Solà R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol. 2004;16:347–53.CrossRefPubMed
35.
go back to reference Velamati PG, Herlong HF. Treatment of refractory ascites. Curr Treatment Options Gastroenterol. 2006;9:530–7.CrossRef Velamati PG, Herlong HF. Treatment of refractory ascites. Curr Treatment Options Gastroenterol. 2006;9:530–7.CrossRef
36.
go back to reference Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J of Gastroenterol. 2009;15:67–80.CrossRef Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J of Gastroenterol. 2009;15:67–80.CrossRef
37.
go back to reference Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manag. 1998;16:96–101.CrossRef Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manag. 1998;16:96–101.CrossRef
38.
go back to reference Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65:32–40.CrossRef Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65:32–40.CrossRef
39.
go back to reference Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol. 2003;15:59–72.CrossRef Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol. 2003;15:59–72.CrossRef
40.
go back to reference Newman G, Pudney D. A survey of current practice in the management of recurrent malignant ascites among oncologists and palliative-care physicians in the UK. Clin Oncol. 2006;18:154–154.CrossRef Newman G, Pudney D. A survey of current practice in the management of recurrent malignant ascites among oncologists and palliative-care physicians in the UK. Clin Oncol. 2006;18:154–154.CrossRef
41.
go back to reference Engin H, Bilir C, Ustundag Y. MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer. Supportive Care Cancer. 2013;21:1153–6.CrossRef Engin H, Bilir C, Ustundag Y. MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer. Supportive Care Cancer. 2013;21:1153–6.CrossRef
42.
go back to reference Zervos EE, Osborne D, Boe BA, Luzardo G, Goldin SB, Rosemurgy AS. Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol. 2006;28:16.CrossRef Zervos EE, Osborne D, Boe BA, Luzardo G, Goldin SB, Rosemurgy AS. Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol. 2006;28:16.CrossRef
43.
go back to reference Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18:945–9.CrossRefPubMed Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18:945–9.CrossRefPubMed
44.
go back to reference Parsons SL, Lang MW, Steele RJC. Malignant ascites: A 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22:237–9.CrossRefPubMed Parsons SL, Lang MW, Steele RJC. Malignant ascites: A 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22:237–9.CrossRefPubMed
Metadata
Title
Management of non-ovarian cancer malignant ascites through indwelling catheter drainage
Authors
Xiaoli Gu
Yuanyuan Zhang
Menglei Cheng
Minghui Liu
Zhe Zhang
Wenwu Cheng
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Palliative Care / Issue 1/2016
Electronic ISSN: 1472-684X
DOI
https://doi.org/10.1186/s12904-016-0116-5

Other articles of this Issue 1/2016

BMC Palliative Care 1/2016 Go to the issue